Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part II. Other organs.
about
Inherited epidermolysis bullosaOne goal, different strategies--molecular and cellular approaches for the treatment of inherited skin fragility disordersDystrophic epidermolysis bullosa: a reviewCell therapy in dermatology.Raising Awareness Among Healthcare Providers about Epidermolysis Bullosa and Advancing Toward a Cure.Oral potentially malignant disorders: an overview of more than 20 entitiesMulticentre consensus recommendations for skin care in inherited epidermolysis bullosa.A consensus approach to wound care in epidermolysis bullosa.Rare case of dysphagia, skin blistering, missing nails in a young boy.Nutritional aspects of children and adolescents with epidermolysis bullosa: literature review.Gene editing toward the use of autologous therapies in recessive dystrophic epidermolysis bullosa.TALEN-based gene correction for epidermolysis bullosa.Inherited epidermolysis bullosa: clinical and therapeutic aspects.Recommended strategies for epidermolysis bullosa management in romania.Nutritional outcomes in children with epidermolysis bullosa: the experiences of two centers in Korea.Novel and emerging therapies in the treatment of recessive dystrophic epidermolysis bullosa.Bone marrow transplantation in epidermolysis bullosa.Gene therapy: pursuing restoration of dermal adhesion in recessive dystrophic epidermolysis bullosa.The collagenopathies: review of clinical phenotypes and molecular correlations.Treatment of hereditary epidermolysis bullosa: updates and future prospects.Epidermolysis bullosa and the partnership with autoimmunity: what should we assimilate?Molecular architecture and function of the hemidesmosome.Blistering disease: insight from the hemidesmosome and other components of the dermal-epidermal junction.Molecular architecture and function of the hemidesmosome.Hereditary epidermolysis bullosa.Junctional epidermolysis bullosa incidence and survival: 5-year experience of the Dystrophic Epidermolysis Bullosa Research Association of America (DebRA) nurse educator, 2007 to 2011.Amplicon-based next-generation sequencing: an effective approach for the molecular diagnosis of epidermolysis bullosa.Manufacturing of Human Extracellular Vesicle-Based Therapeutics for Clinical Use.Tranilast Can be a Useful Addition to the Limited Anti-Epidermolysis Bullosa Weaponry.Herlitz junctional epidermolysis bullosa: diagnostic features, mutational profile, incidence and population carrier frequency in the Netherlands.Long-term follow-up of patients with Herlitz-type junctional epidermolysis bullosa.A survey of epidermolysis bullosa care in the United States and Canada.Mycophenolate mofetil: a novel immunosuppressant in the treatment of dystrophic epidermolysis bullosa, a randomized controlled trial.Fibroblast cell therapy enhances initial healing in recessive dystrophic epidermolysis bullosa wounds: results of a randomized, vehicle-controlled trial.Potential of Systemic Allogeneic Mesenchymal Stromal Cell Therapy for Children with Recessive Dystrophic Epidermolysis Bullosa.Health literacy in patients with epidermolysis bullosa in Iran.Development and validation of an epidermolysis bullosa family/parental burden score.Birmingham epidermolysis severity score and vitamin D status are associated with low BMD in children with epidermolysis bullosa.Inpatient management of children with recessive dystrophic epidermolysis bullosa: A review.Serum levels of high mobility group box 1 correlate with disease severity in recessive dystrophic epidermolysis bullosa.
P2860
Q21202884-439B5F42-64F1-4E37-BE7E-524E9B3642D8Q27026711-29803923-3B11-4134-BBE7-7D98335C29A9Q28084871-0F72D4A9-0E6C-4127-8A05-2AECCF83653DQ33653689-443119F9-ADB6-45A8-B961-E0D6EE74A887Q33821599-7D42AB9A-0978-4EA8-911F-E1BA7ABB8FECQ33880775-B9355937-56BA-4D30-9109-F091B5EAB887Q33948142-D09FA1C0-53F9-490F-8A52-3F9F294E2813Q34636390-170EF681-E70B-4441-A4F2-E1CA4DCA71F3Q35075576-16C7452E-0798-4C35-83A4-684AA5889378Q35211817-04502C29-717F-4C16-90A9-FC1D8C9FC906Q36326838-FC663022-5B57-4124-B1D2-6F2A6CF2AC99Q36915141-A805800A-56DE-4164-A8FB-4B9B3B4AF757Q37114261-CB41C29B-47AF-483C-B39B-FF70F736F2BFQ37397114-A4FEE1C7-19A2-45FD-A0D1-7A4F9B7343FFQ37418782-2AEA9E91-6599-4E86-BBBD-230C04C25502Q37712686-309320DE-E49C-4C9C-986F-15ED7E2BDB78Q38067450-A8B71E67-7C2D-409C-83BB-D5E5A6D5AE34Q38150897-751DD1E6-B8A4-4212-A438-4A04ADC47AFEQ38171408-576A0422-6D0D-463C-820C-FE1353891386Q38176832-CC4FE7EE-70C5-4E88-A26C-D130BD16E5CFQ38269965-F4578706-D770-4D9F-B96D-8E5CDE15861FQ38285370-2FE86E9B-5772-4D1A-B39D-28195F93A688Q38287144-82163B34-68AD-4C1E-AFB9-4BD857BA822BQ38504833-CA162571-188B-4D35-A7B4-B66CF4D0E801Q38619158-E6DA1ED0-4762-4DA7-9378-63705E0FDF6FQ39410424-BC01086A-4927-4AFB-A1D9-91CDF7889281Q41012838-D798B0BF-110C-4FE7-B0D5-459964A8868BQ41034165-B6AB47B3-F91D-434C-8A86-10B1889D9D8FQ42276513-4C04B1D5-0474-4779-BFBC-9A938D540D5BQ42492320-C9D992A8-AF73-40FD-9CF7-05A1EB45074EQ45087709-FD0910B6-F160-44D6-B913-01CCC09DADB2Q45325100-66CC6D3E-3C21-4DE7-8018-A21248BC8D84Q46540016-E6EA7206-5083-42DA-AEF3-350BE6F3566EQ46860053-FF56503A-552C-4DE1-82B1-D832572FE39DQ47093569-48687C00-277C-4188-A404-B56B5F41E772Q47097636-1FC463E6-029E-44D3-999A-4B167CEC614EQ47987245-7660CE60-128E-4232-9121-0A404186EDFAQ48051049-C13C8026-E4CC-498F-92AF-F68A39AD5924Q48297074-09880D45-4DDC-498E-8731-7A60CCE14665Q50957880-3B2CE146-5D65-4DAD-8194-86712E60707F
P2860
Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part II. Other organs.
description
2009 nî lūn-bûn
@nan
2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Extracutaneous manifestations ...... ullosa: part II. Other organs.
@ast
Extracutaneous manifestations ...... ullosa: part II. Other organs.
@en
Extracutaneous manifestations ...... ullosa: part II. Other organs.
@nl
type
label
Extracutaneous manifestations ...... ullosa: part II. Other organs.
@ast
Extracutaneous manifestations ...... ullosa: part II. Other organs.
@en
Extracutaneous manifestations ...... ullosa: part II. Other organs.
@nl
prefLabel
Extracutaneous manifestations ...... ullosa: part II. Other organs.
@ast
Extracutaneous manifestations ...... ullosa: part II. Other organs.
@en
Extracutaneous manifestations ...... ullosa: part II. Other organs.
@nl
P1476
Extracutaneous manifestations ...... ullosa: part II. Other organs.
@en
P2093
Jemima E Mellerio
Jo-David Fine
P304
387-402; quiz 403-4
P356
10.1016/J.JAAD.2009.03.053
P407
P577
2009-09-01T00:00:00Z